Gapping up
In reaction to earnings/guidance:
- CYH +18.1%, TWLO +14.2% (also authorizes new $1 bln share repurchase program), ROKU +12.6%, SGEN +8.8%, RPT +8.5%, PEGA +8.4%, CROX +8.4%, PBF +7.7%, BOWL +7.4%, ORAN +6.2%, TXG +5.9%, WST +5.7%, ALKS +5.6%, BLMN +5.6%, CPA +5.2%, NEX +4.3%, SHAK +4.3%, ZG +4.1%, DOCN +3.6%, CSCO +3.3% (also increases dividend), IRDM +3.3%, FSLY +3.1%, ZBRA +3.1%, PLMR +3%, HST +3%, KBR +2.9%, QDEL +2.6%, ALB +2.5%, KGC +2.5%, SPWR +2.2%, RS +1.9%, PGRE +1.5%, MSA +1.5%, MFC +1.5% (also increases dividend and launches normal course issuer bid), FUN +1.4%, DNOW +1.4%, DTM +1.4%, CF +1.3%, RGLD +1.2% (also increases dividend), ATHM +1.2%, SO +1.1%, ALSN +1%, IDA +1%, ARCH +1%, TSEM +1%
Other news:
- EBS +16.6% (FDA Committee votes unanimously in favor of NARCAN for OTC use)
- ZEUS +5% (increases dividend)
- AMCX +3.3% (names new CEO)
- RPAY +1.6% (sells Blue Cow Software also reaffirms FY22 guidance)
- FMX +1.4% (approves series of actions and divestitures)
- HOOD +0.9% (reports January metrics)
Analyst comments:
- FSLY +3.2% (upgraded to Buy from Neutral at DA Davidson)
- AQN +3% (upgraded to Buy from Underperform at BofA Securities)